Syneron ePrime
RF Microneedling · Fractional RF needle dermal remodeling
New Syneron ePrime pricing is not published; used and refurbished systems trade around $5k–$12k. Syneron ePrime holds FDA 510(k) clearance for its marketed indication. Figures are market estimates verified August 6, 2026.
What it's actually cleared for: Cleared as Primaeva/Renesis dermal remodeling; marketed as ePrime
Last verified: August 6, 2026 · How we verify
New: —|Used: $5k–$12kmarket estimate, no email required
| Manufacturer | Syneron |
|---|---|
| Company | Owner: Apax Partners (funds advised by Apax) (private equity owned, since 2017) · Distribution: direct |
| Category | RF Microneedling, Tightening & HIFU |
| Technology | Fractional RF needle dermal remodeling |
| FDA status | FDA Cleared |
| New price range | Not published |
| Used price range | $5k–$12k |
| Consumables | Not published |
| Launch year | 2012 |
| Last verified | August 6, 2026 |
Overview
Profound predecessor
FDA & regulatory status
What it's actually cleared for:
Cleared as Primaeva/Renesis dermal remodeling; marketed as ePrime
510(k) numbers
K080145; K082391
Regulatory data is compiled from public FDA 510(k) records and may lag recent clearances. Always confirm status with the manufacturer before purchase.
Treatment economics
Economics data for this platform hasn't been published yet.
Chains using this device
No confirmed chain deployments recorded yet.
Owner reviews
Write a reviewNo verified reviews yet — be the first. Founding reviewers get a thank-you gift card for an honest review, positive or negative. How verification works.
Alternatives
History
Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.
August 1, 2026
Record created
Added to The Aesthetic Index — August 2026
Source: The Aesthetic Index editorial
Get the full State of Aesthetic Devices 2026 report
The first full census of the US aesthetic device market — preview it free.